News

MariMed's 2024 Financial Update: Growth and Key Highlights

MariMed's 2024 Financial Update: Growth and Key Highlights

Overview of MariMed's Financial Performance

MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD) has announced its financial results, showcasing exceptional performance for the fourth quarter and the entirety of 2024, marking a transformative year for the company.

Record Revenues and Growth

MariMed's CEO, Jon Levine, expressed pride in achieving record revenues and a significant increase in adjusted EBITDA. The company realized a remarkable 29% annual growth in wholesale revenue, primarily attributed to their robust portfolio of cannabis brands. Notably, Betty’s Eddies™ fruit chews emerged as the best-selling edible in key markets.

Market Expansion Strategies

Looking forward to 2025, MariMed plans to capitalize on several promising avenues for growth. This includes financial contributions stemming from the construction and expansion of ten revenue-generating assets over the past two years. The company also anticipates further wholesale gains in vital markets like Illinois, Missouri, and Maryland.

Financial Highlights

The consolidated financial highlights include substantial growth metrics, with revenues reaching $39.0 million for the quarter ending December 31, 2024, compared to $38.9 million for the same period in 2023. Annual revenue totalled $158.0 million, marking a significant increase from $148.6 million the previous year.

Gross Margins and Net Loss

The Company reported a GAAP gross margin of 33% for the fourth quarter and 40% for the entire year. Despite the impressive revenue figures, MariMed experienced a net loss of $8.2 million for the fourth quarter; however, this was an improvement compared to the prior year.

Continued Commitment to Quality and Growth

According to CFO Mario Pinho, MariMed remains committed to its financial health, possessing one of the strongest balance sheets in the cannabis sector. Achieving revised financial guidance for both revenue growth and adjusted EBITDA has positioned the company well for sustained top-line growth into the upcoming year.

Operational Highlights

MariMed made significant strides operationally in the fourth quarter. This includes the commencement of growing operations at a new cultivation facility in Illinois, dedicated to producing their award-winning Nature's Heritage flower. The first harvest is expected to hit the market shortly, enhancing product availability.

Manufacturing Operations in Missouri

Additionally, the launch of manufacturing operations in Missouri has begun with the wholesale distribution of branded products commencing late December 2024, further extending their market reach.

Recent Developments

On March 3, MariMed announced the successful acquisition of First State Compassion Center in Delaware, a leading cannabis operator in the state. This move is expected to boost their market position as Delaware transitions into adult-use sales.

Understanding Non-GAAP Financial Measures

MariMed employs a range of financial measures, both GAAP and non-GAAP, to evaluate its operational effectiveness. Non-GAAP adjustments provide insight into operational performance, excluding non-recurring expenses to give a clearer picture of the company's profitability.

About MariMed Inc.

MariMed is dedicated to enhancing the quality of life through high-quality cannabis products. They manage licensed cannabis facilities focused on horticultural excellence and innovative product development. Their lineup includes several top-selling brands that resonate with consumers.

Frequently Asked Questions

What were the key financial highlights for MariMed in 2024?

MariMed reported revenues of $39 million for Q4 2024 and $158 million for the year, with a 29% increase in wholesale revenue and a gross margin of 33%.

How did MariMed's CEO describe the company's performance?

CEO Jon Levine highlighted record revenues and improved adjusted EBITDA, attributing these successes to their robust brand portfolio and market strategies.

What operational developments occurred in the fourth quarter?

MariMed started growing operations in a new facility in Illinois and launched manufacturing in Missouri, enhancing their product distribution capabilities.

What are the future growth plans for MariMed?

The company aims to expand market penetration through new asset contributions, wholesale growth in key markets, and strategic acquisitions.

Where can I find more information on MariMed?

For further information, you can visit the company's official website at www.marimedinc.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 385

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Build-A-Bear Lawsuit Notice Carries a Date Problem

Updated Category News Views 26

Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...

Continue Reading

Top 5 Most Recently Viewed Articles

NuCana Discontinues Phase 2 Colorectal Cancer Study

Updated Category News Views 146

NuCana Provides Update on Phase 2 Randomized Colorectal Cancer Study NuTide:323 Study Discontinued Following Initial Analysis Ongoing Studies Show Promise with NUC-7738 and Pembrolizumab NuCana plc (NASDAQ: NCNA) has shared important updates about its clinical trials focused on innovative treatments for colorectal cancer. The company has made the decision to discontinue...

Continue Reading
Brøndbyernes IF Football Meeting - Key Highlights Recap

Updated Category News Views 179

Overview of the Annual General Meeting for Brøndbyernes IF Football A/S BRØNDBYERNES I.F. FODBOLD A/S CVR-nr. 83 93 34 10 This report summarizes the outcomes of the annual general meeting conducted by Brøndbyernes IF Football A/S. Key Date and Location The annual shareholders meeting took place, gathering stakeholders and shareholders at the club's headquarters. A...

Continue Reading
Uncovering the Wealth from Investing in BlackRock

Updated Category News Views 314

The Potential Growth of $1000 in BlackRock Investors often wonder how their money would grow over time if invested in strong companies. Recently, we looked into BlackRock, Inc., known by its stock ticker BLK. Over a span of 15 years, investing just $1000 into BlackRock stocks would yield an impressive value today. According to current evaluations, if you had made that...

Continue Reading
Zealand Pharma Advances Glepaglutide Approval for SBS Treatment

Updated Category News Views 267

Glepaglutide Submission to EMA Marks Significant Progress Zealand Pharma A/S, a pioneering biotechnology company, has recently shared exciting news about its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its innovative drug, glepaglutide. This long-acting GLP-2 analog is specifically designed for treating adults suffering from short...

Continue Reading
Seven Gables Real Estate Partners with Local Logic for Insights

Updated Category News Views 40

Seven Gables Real Estate Partners with Local Logic In a significant move that underscores their dedication to innovation, Seven Gables Real Estate has announced an exciting partnership with Local Logic, a leader in location intelligence. This collaboration is set to incorporate Local Logic's cutting-edge products—Local Content, Local Search, and NeighborhoodWrap—into...

Continue Reading